Akoya Biosciences Announces Public Offering of Common Stock
June 07 2023 - 4:08PM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial
Biology Company®, today announced it has launched an underwritten
public offering of shares of its common stock (the “Offering”). In
addition, Akoya expects to grant the underwriters a 30-day option
to purchase additional shares of its common stock. The proposed
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Akoya intends to use the net proceeds from the
Offering for working capital and general corporate purposes.
Morgan Stanley and Piper Sandler, are acting as
joint book-running managers for the Offering.
The securities described above are being offered
by Akoya pursuant to a shelf registration statement on Form S-3
that was filed with the U.S. Securities and Exchange
Commission (the “SEC”) and was declared effective
on November 21, 2022. A preliminary prospectus supplement and
the accompanying prospectus relating to the Offering will be filed
by Akoya with the SEC and will be available on the SEC’s website
at www.sec.gov. A final prospectus supplement and the
accompanying prospectus relating to the Offering will be filed by
Akoya with the SEC. The Offering will be made only by means of a
prospectus, including a prospectus supplement, that forms part of
the registration statement referred to above. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to the Offering may be obtained by contacting: Morgan
Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, New York 10014, by phone at
1-866-718-1649 or by email at prospectus@morganstanley.com and
Piper Sandler & Co., Attention: Prospectus Department, 800
Nicollet Maill J12S03, Minneapolis, Minnesota 55402, by telephone
at 1-800-747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya
Biosciences’ mission is to bring context to the world of biology
and human health through the power of spatial phenotyping. Akoya
offers comprehensive single-cell imaging solutions that allow
researchers to phenotype cells with spatial context and visualize
how they organize and interact to influence disease progression and
response to therapy. Akoya offers a full continuum of spatial
phenotyping solutions to serve the diverse needs of researchers
across discovery, translational and clinical research: PhenoCode™
Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT
Instruments. To learn more about Akoya,
visit www.akoyabio.com.
CAUTIONARY STATEMENT CONCERNING
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press
release constitute forward-looking statements, including with
respect to the closing of the Offering. Management has based these
forward-looking statements on its current expectations,
assumptions, estimates and projections. While they believe these
expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions
and involve known and unknown risks and uncertainties, many of
which are beyond management's control. These statements involve
risks and uncertainties that may cause Akoya’s actual results,
performance or achievements to differ materially from any future
results, performance or achievements expressed or implied by these
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and, except as
required by law, Akoya assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences
investors@akoyabio.com
Media Contact:
Christine Quern
617-650-8497
media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2024 to May 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From May 2023 to May 2024